Friday, October 7, 2016 | 9:00 AM - 5:00 PM
Mental illness causes debilitating consequences on quality of life for individuals, families, and society. This symposium explores avenues for translating these discoveries about the neurobiology of a spectrum of mental illnesses into new treatments.
Tuesday, October 25, 2016 | 9:00 AM - 5:00 PM
Speakers: Marcus Bantscheff (Cellzome/GSK), Benjamin F Cravatt (The Scripps Research Institute), Craig Crews (Yale University), Howard Hang (The Rockefeller University), Ruth Nussinov (National Cancer Institute), Brian Raymer (Pfizer), Bryan Roth (University of North Carolina), Eranthie Weerapana (Boston College)
Chemical Biology is changing the face of drug discovery. This symposium will highlight recent developments in the field, featuring examples from neurobiology and cancer, the ubiquitin proteasome system, GPCRs, and protein lipidation.
Thursday, November 3, 2016 | 9:00 AM - 5:00 PM
Speakers: Henrik Bjørn Nielsen (Clinical-Microbiomics A/S), Martin J. Blaser (New York University Langone Medical Center), Patrice D. Cani (Louvain Drug Research Institute, Metabolism and Nutrition), Rachel Carmody (Harvard University), Stanley L. Hazen (Cleveland Clinic), Gerald I. Shulman (Yale University School of Medicine), Marion Soto (Joslin Diabetes Center, Harvard Medical School), and Dan Winer (University of Toronto)
The microbiome is emerging as an important regulator of health, and disease well beyond the digestive tract. This symposium will highlight recent research innovations and therapeutic applications from the microbiome with a focus on metabolic disease.
Wednesday, November 9, 2016 | 8:30 AM - 5:15 PM
Keynote Speaker: Lawrence D. Mayer (Jazz Pharmaceuticals)
Explore approaches for complex drug development and regulation, outstanding challenges in the assessment of complex drug equivalence, consequences for product interchangeability, and compare biological and non-biological complex drug families.
Thursday, November 10, 2016 | 8:00 AM - 6:00 PM
Speakers: Iannis Aifantis (NYU School of Medicine), Emily Bernstein (Icahn School of Medicine at Mount Sinai), Ryan Kruger (GlaxoSmithKline), Ross L. Levine (Memorial Sloan Kettering Cancer Center), Sheng Li (Weill Cornell Medical College), Christopher E. Mason (Weill Cornell Medicine), Kornelia Polyak (Dana Farber Cancer Institute, Harvard Medical School), Tim Somervaille (The University of Manchester), and Jorge DiMartino (Celgene)
This conference will explore novel target and validation strategies, translational approaches to assess predictive and response biomarkers, resistance mechanisms, and combination strategies for targeting epigenetic susceptibilities in cancer.
Thursday, September 8, 2016 | 9:00 AM - 5:00 PM
Speakers: Hans-Joachim Anders (University of Munich), John Cijiang He (Icahn School of Medicine at Mount Sinai), Matthias Kretzler (University of Michigan), Kevin V. Lemley (University of Southern California), Jochen Reiser (Rush University Medical Center), Myung K. Shin (Merck & Co. Inc.), Katalin Susztak (University of Pennsylvania), and Roger C. Wiggins (University of Michigan)
Accumulating evidence supports a role for renal inflammation and podocytopathy in pathogenesis and progression of chronic kidney disease. This symposium will delve into the mechanisms underlying this pathology.
Wednesday, July 13, 2016 | 9:00 AM - 5:00 PM
Keynote Speaker: David Bartel (Whitehead/MIT/HHMI)
Speakers: Paul Grint (Regulus Therapeutics), David S Hong (The University of Texas MD Anderson Cancer Center ), Daniel J Siegwart (University of Texas Southwestern Medical Center), Frank Slack (BIDMC Cancer Center/Harvard Medical School), James W Welsh (The University of Texas MD Anderson Cancer Center)
miRNAs play critical roles in regulating gene expression. This symposium will present up-to-date basic, translational, and clinical research addressing the biology of miRNA and their promise as a therapeutic target.
Tuesday, June 28, 2016 | 8:00 AM - 5:30 PM
Keynote Speaker: Giancarlo Comi (Università Vita-Salute San Raffaele)
Explore novel and emerging treatments for multiple sclerosis, including biomarkers and MRI usage in disease diagnosis, prognosis, and monitoring.
Tuesday, June 21, 2016 | 8:30 AM - 5:00 PM
Keynote Speaker: Sharon Inouye (Harvard Medical School)
This meeting will convene leading scientists and physicians to discuss the challenges and opportunities to create biomarkers and therapeutics for these patients who are vulnerable to delirium, cognitive decline, and dementia following surgery.
Keynote Speakers: Richard Gilbertson (Cambridge Cancer Centre, University of Cambridge, UK) and Craig B. Thompson (Memorial Sloan Kettering Cancer Center)
This eBriefing covers the latest research on pediatric cancers.
Organizers: Donald McCaffery (Resverlogix Corp.), Norman Wong (Resverlogix Corp.), Sarah Zapotichny (Resverlogix Corp.), George Zavoico (Jones Trading Institutional Services), Sonya Dougal (The New York Academy of Sciences), and Caitlin McOmish (The New York Academy of Sciences)
Keynote Speaker: Craig B. Thompson (Memorial Sloan Kettering Cancer Center)
Epigenetic abnormalities contribute to tumorigenesis and various diseases beyond cancer. This eBriefing describes recent progress in validating the therapeutic potential of small molecule inhibitors targeting epigenetic marks.
Edited by Annals of the New York Academy of Sciences
This Annals issue presents a meeting report on mobile health technology in clinical trials and five original research articles discussing topics related to β-thalassemia major, Alzheimer's disease, hematopoiesis, hepatosteatosis, and downbeat nystagmus.
Organizers: Renier Brentjens (Memorial Sloan Kettering Cancer Center), George Zavoico (Jones Trading Institutional Services), Sonya Dougal (The New York Academy of Sciences), and Caitlin McOmish (The New York Academy of Sciences)
This eBriefing explores advances in cancer immunotherapy, which engages the immune system to detect and destroy cancer cells and has gained popularity and success in recent years.